Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5492 in SLE, IIM, or RA
NCT06916806Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Small Molecules, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 1, open-label trial of AZD5492 in systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM) and rheumatoid arthritis (RA) (2 arms), sponsored by AstraZeneca. Primary endpoints: Treatment-Emergent Adverse Events, Related Treatment-Emergent Adverse Events and 6 more. Started May 2025; status: recruiting.
02
Drugs
AZD5492
03
Conditions
systemic lupus erythematosus (SLE)idiopathic inflammatory myopathy (IIM)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06916806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06916806.